SecBot SecBot
EFFECT ·Filed May 18, 2026

NCEL

NewcelX Ltd.
BEARISH
Impact 5/10
Horizonweeks Processed5mo ago SEC9999999995-26-001675
IPO/offering going effective
Actionable Insight ▼ Bearish

Monitor for any subsequent prospectus supplement or 424B filing that would indicate an actual offering. The effective shelf creates overhang that may pressure the stock, especially given the weak analyst sentiment and small market cap. Any takedown could be significantly dilutive relative to current market cap.

DirectionBearish
Confidencemedium
Horizonweeks
Final — all horizons settled through T+60d
NCEL ▲ +7.07% at T+60d
SHORT call ✗ call lost -7.07% · α vs SPY -2.22% · entry $3.11 → $3.33
Entry = T+0 close
May 18, 2026
via day close
T+1d
+2.25%
call -2.25% · α -2.90%
$3.18
settled 5mo ago
T+5d
+1.29%
call -1.29% · α +0.33%
$3.15
settled 5mo ago
T+20d
+3.22%
call -3.22% · α -1.63%
$3.21
settled 4mo ago
T+60d
+7.07%
call -7.07% · α -2.22%
$3.33
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

NewcelX Ltd.'s F-3 shelf registration (File No. 333-295770) became effective on May 15, 2026, allowing the company to offer and sell securities from time to time. This creates potential dilution overhang for the $17M market cap pharmaceutical company, though no specific offering has been announced.

Key Facts

  • F-3 shelf registration became effective on May 15, 2026
  • Company has a $17M market cap and operates in pharmaceutical preparations
  • No specific offering size or terms disclosed in the filing
  • Formerly known as NLS Pharmaceutics Ltd. (name change July 2019)
  • Analyst consensus is 0% bullish with 3 Hold, 1 Sell, 2 Strong Sell ratings

Financial Impact

Potential dilution from future shelf takedowns; no specific offering amount disclosed

dilution

Risk Factors

  • Future equity offering could be highly dilutive given $17M market cap
  • Weak analyst consensus (0% bullish) suggests limited institutional support
  • No disclosed use of proceeds or specific offering plan

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001675
Document: 9999999995-26-001675-index.html9999999995-26-001675
Document: 9999999995-26-001675.txt9999999995-26-001675
17 reports for NCEL
Performance horizon
63% Hit rate @ T+5 5 of 8 directional calls Went positive at some point 5 of 8 best @ T+20▲ +95.57%Apr 1, 2026
Filters
Rows
Reports for NCEL — sortable, filterable
TypeNow
Sep 23, 2026
4w ago
EFFECT
BEARISH ★ 5/10
$2.86 $3.08▼ −7.52%▼ −8.19%$2.55 (+10.84%)
Sep 18, 2026
5w ago
6-K
BEARISH ★ 6/10
$2.97 $2.92▲ +1.68%▲ +0.66%$2.55 (+14.14%)
Aug 27, 2026
8w ago
EFFECT
BEARISH ★ 5/10
$3.42 $3.35▲ +2.05%▲ +1.28%$2.55 (+25.44%)
Jul 31, 2026
12w ago
6-K
MIXED ★ 5/10
$3.49 $3.31▼ −5.16%▼ −8.67%$2.55 (−26.93%)
Jul 15, 2026
14w ago
6-K
BULLISH ★ 5/10
$3.93 $3.65▼ −7.12%▼ −6.14%$2.55 (−35.11%)
Jul 8, 2026
15w ago
6-K
NEUTRAL ★ 3/10
$4.23 $3.98▼ −5.91%▼ −6.77%$2.55 (−39.72%)
Jul 1, 2026
16w ago
6-K
BULLISH ★ 7/10
$3.85 $4.01▲ +4.16%▲ +3.89%$2.55 (−33.77%)
Jun 30, 2026
16w ago
6-K
NEUTRAL ★ 2/10
$3.85 $4.01▲ +4.16%▲ +3.89%$2.55 (−33.77%)
Jun 18, 2026
18w ago
EFFECT
BEARISH ★ 5/10
$3.31 $3.55▼ −7.25%▼ −8.92%$2.55 (+22.96%)
Jun 5, 2026
20w ago
6-K
NEUTRAL ★ 4/10
$3.24 $3.20▼ −1.23%▼ −3.35%$2.55 (−21.30%)
Showing 10 of 17

US Market Status

Market Closed — Opens in 5h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026